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A B S T R A C T
Objectives: Patients with non-small cell lung cancer (NSCLC) may experience progression and stage shift due to delays in a complex and time-consuming diagnostic
work-up. We have analyzed the impact of both a local and national intervention on total time to treatment (TTT).
Material and Methods: All patients diagnosed with NSCLC at a Norwegian county hospital from 2007 to 2016 were reviewed. Logistic bottlenecks and delays were
identified (2007–12) resulting in implementation of a local initiative with new diagnostic algorithm introduced by the beginning of 2013. In 2015, national
diagnostic cancer pathways were implemented. TTT defined as time from received referral from the primary physician to start of treatment was compared in the three
diagnostic time periods; baseline (2007–12), local (2013–14) and national (2015–16).
Results: A total of 780 patients were included. Among patients treated with curative intent the median TTT decreased by 21 days, from 64 to 43 days (p < 0.001)
while the mean number of diagnostic procedures increased from 3.5 to 3.9. In median regression analysis, the local initiative was associated with a reduction of
estimated 7.8 days (95% CI 3.2, 12.3) in TTT, while the national initiative correlated with a reduction of estimated 14.9 days (95% CI 10.2, 19.6) compared to time at
baseline. Covariates associated with longer TTT were stage I, use of PET-CT, diagnostic procedure at external hospital, and number of diagnostic procedures.
Conclusion: Local and national initiatives significantly reduced TTT in NSCLC. The effect was most pronounced among patients with disease available for curative
treatment.
1. Introduction
The diagnostic work-up of suspected non-small cell lung cancer
(NSCLC) is a complex and logistically challenging process. NSCLC
grows rapidly with median volume doubling times reported as low as
66 days [1]. Thus, a time-consuming diagnostic process may lead to
deteriorating performance status, weight loss, larger treatment volumes
and stage shift. That again may affect both treatment options, prognosis
and ultimately survival [1–5].
In clinical practice, time spent on diagnostic work-up and awaiting
treatment are often longer than guidelines recommend. Several reports
address interventions to reduce time intervals, including suggestions for
a rapid outpatient diagnostic program, multidisciplinary meetings,
nurse coordinated cancer programs and specific diagnostic algorithms
[6–9].
Guidelines address maximum acceptable waiting times for referral,
diagnostic work-up and initiation of treatment for lung cancer [10–13].
The Norwegian recommendations were introduced in January 2015
defining a maximum total time to treatment (TTT) of 35 to 42 calendar
days from referral to start of treatment (Fig. 1) [14].
In the present paper we analyse the impact on TTT of two separate
major revisions in the lung cancer program in a cohort from a single
centre hospital in Southern Norway. Firstly, in 2013 the diagnostic
work-up was optimised based on a local analysis of delays. Secondly, in
2015 the national diagnostic cancer pathways (NDCP) were introduced
[14]. With political incentives, recommendations were given on time-
liness, with the aim to offer a more predictable diagnostic work-up for
patients with suspected cancer.
2. Material and methods
2.1. Data and diagnostics
All patients diagnosed with lung cancer (ICD-10 code C34) at
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Sørlandet Hospital Kristiansand (SHK) in the ten-year period of
2007–16 have been registered in a local, clinical database.
Demographic variables, clinical characteristics, diagnostic intervals and
survival data from 2007–12 were retrieved retrospectively from the
electronic patient records. Since 2013 registration of the same variables
has been prospective and continuous.
SHK is a county hospital serving a population of 200 000. There is
no other hospital or private alternative for lung cancer patients in the
region. Norway has a universal health care insurance system covering
all citizens. Thus, the database contains an unselected and complete
population-based lung cancer cohort.
The hospital has the personnel, skills and equipment for a complete
diagnostic work up except for Positron Emission Tomography Computer
Tomography (PET-CT) which was performed at the regional centre Oslo
University Hospital (OUH). Endobronchial ultrasound-guided (EBUS)
fine-needle aspiration cytology has been available at SHK since 2013.
Chemotherapy, radiation and chemoradiation were administered at
SHK, while surgery and stereotactic beam radiation therapy (SBRT)
were performed at OUH throughout the period. A local multi-
disciplinary team (MDT) meeting discussed all patients diagnosed with
lung cancer. Patients suggestive for surgery or SBRT were discussed in a
weekly teleconference MDT meeting with OUH.
In this study, all invasive and radiological procedures aimed at
providing diagnosis and staging were registered and counted. Included
procedures were chest CT scan, bronchoscopy, EBUS, esophageal ul-
trasound-guided fine needle aspiration, CT and ultrasound-guided
percutaneous biopsies, surgical excision biopsies, pleural effusion cy-
tology, PET-CT and magnetic resonance imaging (MRI). The total
number of procedures assigned to each patient was noted to give a
measure of the complexity of the diagnostic process. In patients where
cytologic or histologic confirmation proved particularly difficult, ad-
ditional EBUS or CT-guided percutaneous biopsy was performed at
OUH. These planned, out-of-house procedures were registered as “ex-
ternal OUH procedure” in order to assess to what extent they con-
tributed to a diagnostic delay.
2.2. Initiatives
2.2.1. Local streamlining of the diagnostic work-up (2013–14)
Delays in the diagnostic pathways for primary pulmonary carci-
noma in Southern Norway have previously been reported from the re-
gion in the period 2002–2005 [15]. In 2012, a local quality improve-
ment initiative from the hospital administration enabled registration
and review of the diagnostic and treatment delays of previous lung
cancer patients. Several bottlenecks in the diagnostic pathway were
identified, and a new diagnostic work-up was introduced to reduce
delays in the period 2013–2014 (Table 1).
2.2.2. National diagnostic cancer pathways (NDCP, 2015–16)
NDCP were launched for lung cancer in January 2015. These in-
cluded new recommended maximum limits for time spent in the diag-
nostic process (Fig. 1) as well as mandatory reporting of the actual time
intervals for all patients with suspected lung cancer. Local adaptions
were introduced to comply with the new recommendations (Table 1).
2.3. Study population and selection
From a total of 1261 patients diagnosed with lung cancer, 780 pa-
tients were included in the final analysis. The 481 patients excluded
had either other histology than NSCLC (n = 204), no tissue diagnosis
(n = 19) or did not receive any cancer specific treatment (n = 258).
However, 42 patients lacking tissue confirmation, but receiving SBRT
based on a positive PET-CT and tumour growth on repetitive CT-scans,
were included. This group of patients had all stage I tumours and are in
the context of this paper considered to be NSCLC.
The patients were divided into three groups according to their time
of diagnostic work-up; baseline (2007–12), local (2013–14) and na-
tional (2015–16) (see above).
All patients were staged according to international staging system
version 7 (TNM-7) [16].
Fig. 1. Overview of intervals and recommended maximum
time limits in calendar days according to Norwegian National
diagnostic pathways [14]
Referral: date of receiving referral letter at department
First hospital consultation: date of first consultation in pul-
monary department.
Treatment decision: date of multidisciplinary team meeting
with final treatment decision. All diagnostic procedures are
finished.
Treatment initiation: a) date of surgery or b) date of first
fraction of radiotherapy or c) date of first day of che-
motherapy/anti-tumor medication.
TTT: time in calendar days from referral due to suspicion of
lung cancer to start treatment.
* Seven days when first treatment is medication (TTT 35
days), 14 days when receiving surgery or radiation therapy (TTT 42 days).
Table 1




National diagnostic cancer pathways
Plan diagnostics before 1st consultation and choose procedure(s) of highest diagnostic and
staging value(s)
New recommendations of delays for referral period, diagnostic period and
treatment initiation*
Designated slots for combined 1st consultation and diagnostic procedure National reporting of delays
Referral to all other relevant procedures at 1st consultation Internal resource shift with one extra physician to see referred cancer patients
Improved radiologic service with shorter time to CT scanning and available slots for CT guided
lung biopsies 1 day a week
CT guided biopsy 2 slots 2 days a week
Improved capacity to start chemotherapy with priority for curative intent patients
⁎ See Fig. 1.
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2.4. Statistics
Descriptive statistics of the patient and tumor were presented as
frequencies and percentages for categorical data and mean with stan-
dard deviation (SD) for normally distributed continuous data. Time
interval variables were non-normally distributed, and thus reported as
median with inter-quartile range (IQR). Comparisons of the three di-
agnostic time periods (2007–12, 2013–14 and 2015–16) were tested by
chi-square test, one-way ANOVA or Kruskal–Wallis test, where appro-
priate. Further, referral, diagnostic and treatment intervals were stu-
died in stratified analyses by treatment intent and modality.
A multivariable median regression model assessed the associations
between co-variates and TTT. Age at diagnosis and number of proce-
dures were continuous variables, while diagnostic time period
(2007–12, 2013–14 and 2015–16), sex, histology (squamous cell car-
cinoma, non-squamous and no-biopsy), stage (I, II, III and IV), treat-
ment (surgery, SBRT, chemoradiation of curative intent and palliative),
PET-CT (yes or no), cerebral MRI (yes or no) and external OUH pro-
cedure (yes or no) were considered categorical. Treatment was not in-
cluded in the multivariable model due to multicollinearity with stage at
diagnosis. Results were presented as median values with 95% con-
fidence intervals (CI).
Moreover, quantile regressions were performed at 25th, 75th and
90th percentile distributions of TTT, including the same co-variates as
above, to assess the association between the diagnostic time periods
(initiatives) in patients with short (25th percentile) and long (75th and
90th percentile) TTT.
A sensitivity analysis was performed to study the impact of the time-
window of the baseline period. The multivariable median regression
was repeated with the historical group divided into three evenly periods
(2007–08, 2009–10 and 2011–12).
Differences were considered statistically significant if p < 0.05. All
data were analysed using Stata statistical software, version 15 (StatCorp
Lp, College Station, TX, USA).
Norwegian Center of Research Data approved the storage of de-
identified quality data. The study was presented for the regional ethics
committee that determined that the present study did not require their
approval since no biomedical interventions or registrations were added
for study purposes.
3. Results
3.1. Characteristics of included patients
The mean age of patients increased by nearly three years during the
study period (Table 2). Approximately two-thirds of the patients were
in stage I-III potential eligible for curative treatment. The proportion of
patients receiving treatment with a curative intent (surgery, SBRT or
chemoradiation) increased from half of the patients (49%) in 2007–12
to two-thirds (65%) in 2015–16, and mostly due to a 15% increase in
SBRT. During the study period there was a significant increase in the
number of patients undergoing cerebral MRI and out-of-house PET-CT
as part of their diagnostic work-up. Among patients treated with
curative intent, only 1% were staged with PET-CT and cerebral MRI in
2007–12, while 13% and 64% were staged with both modalities in the
2013–14 and 2015–16 periods, respectively. The mean number of di-
agnostic procedures increased from 3.1 to 3.7 per patient between the
baseline and last diagnostic time period. Twice as many had four or
more diagnostic procedures in 2015–16 (55%) as opposed to 2007–12
(28%). Similarly, in 2015–16 twice as many had four or more proce-
dures in stages I–III (73%) compared to stage IV (35%).
3.2. Time intervals
The median TTT decreased by 11 days during the study (Table 3).
This was especially evident for patients receiving treatment with
curative intent. This group experienced a 21-day reduction, as com-
pared to five days for palliative treatments. For patients receiving SBRT
and those treated with curative intent chemoradiation, the median TTT
decreased by about 40 days during the study period, while a more
modest reduction was observed for surgical patients (16 days) (all
p < 0.001).
The median referral interval among all patients was reduced by two
days from baseline to the next time period when the local diagnostic
algorithm was streamlined, with no further reductions after introduc-
tion of NDCP in 2015.
The median diagnostic interval for patients receiving curative
treatments was longer than for patients receiving palliative treatments
in all three diagnostic time periods. After the two initiatives in 2013
and 2015, the diagnostic intervals were reduced by a total of 15 days
(from 36 to 21) in the curative group, while there was no change in the
time spent on palliative patients (13–14 days). Thus, the difference
between the curative and palliative treated groups of patients decreased
from 23 to seven days. The shortening of the diagnostic interval was
seen for all three curative treatment modalities, with 11 days for sur-
gery, 21 days for SBRT and 19 days for curative chemoradiation
(p < 0.001).
Table 2
Patient and cancer characteristics within the three time periods in a cohort of
non-small cell lung cancer patients (N = 780).
Baseline Local initiative National
initiative
2007–2012 2013–2014 2015–2016 p-value
n = 446 n = 145 n = 189
Age, years (mean ±
SD)
65.8 (9.7) 66.9 (10.2) 68.6 (8.7) 0.0031
Sex (%) 0.142
Male 55.6 46.2 53.4
Female 44.4 53.8 46.6
Stage (%) 0.1452
I 28.3 27.6 34.4
II 10.5 16.6 13.8
III 21.8 24.1 17.5
IV 39.5 31.7 34.43
Histology (%) <0.0012
Squamous 25.8 25.5 25.9















PET-CT (%) 41.5 64.1 75.7 <0.0012
Magnetic resonance
imaging (%)
12.8 16.6 58.2 <0.0012
Number of procedures
(mean ± SD)⁎⁎⁎
3.1 (1.1) 3.2 (1.1) 3.7 (1.1) <0.0011
PET-CT: Positron emission tomography – computed tomography.
⁎ Concurrent and sequential chemoradiotherapy and fractionated radio-
therapy where radiation dose ≥ 60 Gy.
⁎⁎ Includes chemotherapy, radiation, combinations of chemotherapy and
radiation where (radiation dose <60 Gy), personalized treatment (EGFR TKI
etc.).
⁎⁎⁎ Included procedures, chest CT scan, bronchoscopy, EBUS, esophageal
ultrasound-guided fine needle aspiration, CT and ultrasound-guided percuta-
neous biopsies, surgical excision biopsies, pleural effusion cytology, PET-CT
and magnetic resonance imaging (MRI).
1 ANOVA.
2 Chi-square test.
3 Four patients with limited brain metastasis received treatment with cura-
tive intent for both metastasis and primary tumour.
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In general, the longest treatment intervals were seen in patients
receiving curative treatment. However, there was a shortening of the
interval from 20 to 15 days during the study period (p < 0.001). The
largest reduction was seen in patients receiving curative intent che-
moradiation where the median treatment interval decreased by 19 days
(p < 0.001). For the two out of house treatment modalities, SBRT and
surgery, the reduction was 16 days (from 37 to 21) (p < 0.001) and five
days (from 19 to 14) (p = 0.06), respectively.
In contrast, there was only a small, nonsignificant decrease in the
palliative group with a median treatment interval reduction from eight
to six calendar days (p = 0.10).
3.3. Regression analysis
In the adjusted model, the local optimized diagnostic process was
associated with an estimated reduction of 7.8 days (95% CI −12.3,
−3.2) in TTT, while the NDCP experienced an estimated reduction of
14.9 days (95% CI −19.6, −10.2) compared to the baseline period
(Table 4).
Studying the 25th percentile, the adjusted reduction in TTT asso-
ciated with the local initiative, was four days (95% CI −6.9, −1.1;
p = 0.01) compared to the baseline period. Correspondingly, the ad-
ditional reduction in TTT of NDCP was 6.8 days CI (95% CI −11.3,
−2.2; p < 0.001). At the 75th percentile, adjusted reduction related to
local initiative was 12.7 days (95% CI −16.9, −8.5; p < 0.001) and
national initiative 9.3 (95% CI −16.5, −2.1; p = 0.01). At the 90th
percentile corresponding numbers for local and national were 17.7 days
and 9.2 days, respectively, the sum being close to four weeks.
In the multivariate regression analysis, several other covariates
significantly changed median TTT. The following factors increased TTT:
low stage (I–III), being diagnosed without histologic confirmation (no-
biopsy), increasing age and number of diagnostic procedures or out-of-
house invasive procedures and PET-CT (p < 0.05). The largest delay
(21 days) was observed for stage I compared to stage IV. In contrast,
receiving MRI reduced TTT (p < 0.05) (Table 4).
Sensitivity analysis, changing the time-window of the baseline
period from the six-year period 2007–2012 to a smaller time interval
did not alter the changes in TTT (data not shown). Only non-significant
variations in median TTT was observed within the baseline period when
splitting it into three separate two-year periods.
3.4. Timely treatment
The national guidelines of January 2015 set standards for maximum
recommended time limits for both referral, diagnostic and total time to
treatment (Fig. 1). The percentage of patients receiving timely treat-
ment within the maximum recommended TTT, increased from 43% via
49% to 64% through the three time periods (Fig. 2). Such increase was
most evident in the group of patients receiving curative treatment. The
national guidelines also set a goal of 70% for the fraction of patients
that should receive treatment within the new standard time limits.
Among the NSCLC patients following the NDCP (2015–16), only pa-
tients receiving palliative treatment (85%) and curative intent che-
moradiation (85%) reached this goal, both being in-house treatments.
4. Discussion
The introduction of both local and national initiatives were asso-
ciated with significant reductions in TTT for NSCLC-patients. This re-
duction was most evident among patients with tentatively curable
disease, stage I-III, and was experienced despite an increasing number
of diagnostic procedures performed.
Table 3
Observed time intervals at baseline (2007–12) and after local (2013–14) and national initiative (2015–16) stratified by treatment intent and modality.
Baseline Local initiative National initiative
2007–2012 2013–2014 2015–2016 p-value1
n Median (IQR) n Median (IQR) n Median (IQR)
Total time to treatment
All patients 446 46(27–67) 145 40(25–57) 189 35(24–50) <0.001
Palliative treatments 229 28(19–43) 65 25(20–42) 67 23(18–33) 0.13
Curative treatments 217 64(49–89) 80 50(35–69) 122 43(32–56) <0.001
• Surgery 152 58(47–81) 40 47(35–57) 59 42(34–56) <0.001
• SBRT 24 91(70–116) 22 74(65–78) 39 51(40–61) <0.001
• Chemoradiation of CI 41 67(54–84) 18 35(28–47) 24 28(24–35) <0.001
Referral interval*
All patients 330 6 (4–9) 115 4(2–7) 162 4 (2–6) <0.001
Palliative treatments 136 6(3–8) 41 4(2–6) 53 3(1–5) <0.001
Curative treatments 194 7(4–11) 74 4(2–7) 109 4(2–7) <0.001
• Surgery 137 7(4–11) 38 4(2–7) 55 4(2–8) <0.001
• SBRT 23 7(5–10) 18 4(2–7) 34 4(2–6) 0.02
• Chemoradiation of CI 34 6(4–11) 18 5(2–7) 20 4(3–6) 0.03
Diagnostic interval⁎⁎
All patients 434 23(12–41) 145 23(13–34) 189 19(12–29) 0.04
Palliative treatments 217 13(7–25) 60 16(8–28) 67 14(7–23) 0.48
Curative treatments 217 36(22–50) 80 29(19–38) 122 21(13–34) <0.001
• Surgery 152 34(22–48) 40 27(19–35) 59 23(13–35) <0.001
• SBRT 24 43(28–59) 22 34(30–45) 39 22(15–36) <0.001
• Chemoradiation of CI 41 38(27–55) 18 23(15–32) 24 19(14–22) <0.001
Treatment interval⁎⁎⁎
Palliative treatments 215 8(5–14) 64 8(6–14) 66 6(4–12) 0.10
Curative treatments 216 20(11–32) 80 15(7–26) 122 15(8–21) <0.001
• Surgery 152 19(11–27) 40 14(8–20) 59 14(12–20) 0.06
• SBRT 24 37(27–44) 22 33(26–41) 39 21(19–26) <0.001
• Chemoradiation of CI 40 25(12–33) 18 6(2–7) 24 6(5–7) <0.001
IQR: inter-quartile range; SBRT: stereotactic beam radiation therapy; CI: curative intent.
1 p-value from Kruskal–Wallis test.
⁎ Referral interval was not given when patient was directly admitted to hospital.
⁎⁎ Diagnostic interval was not registered when referral was based on histologic confirmed lung cancer and no further diagnostic procedures were performed.
⁎⁎⁎ Treatment interval was not registered when treatment was started before diagnostics were finished.
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4.1. Initiatives and association with TTT
Lung cancer is a complex and multifaceted disease reflected in an
intricate path from referral to treatment, involving multiple procedures
and clinical specialties. The increasing number of procedures, like PET-
CT, EBUS and a more elaborate pathological work-up, has made the
diagnostic process prone to more delays.
Several studies report interventions to reduce time to treatment or
diagnosis. In The- Time-to-Treat program in Canada [9], optimization
and coordination of care as well as use of a coordinator was associated
with reduced unadjusted time from abnormal X-ray to diagnosis (128 to
20 days). Similarly, implementation of a coordinator nurse at a cancer
centre in Ohio was found to reduce the unadjusted TTT from 64 to 45
days [17]. The introduction of a cancer care program was associated
with reduced time from abnormal x-ray image to treatment by 25 days
(from 126 days to 101 days; p < 0.02) when corrected for confounders
in a multivariate analysis [7]. In our cohort, reduced TTT was asso-
ciated with the introduction of both the local and national initiatives,
when adjusting for known covariates. Additionally, it seems very
plausible that the introduction of the new algorithms benefitted pa-
tients at a broad range, as shown through regression analyses at
different percentiles. We found that the longer the initial TTT, the more
pronounced was the reduction in TTT associated with the initiatives. To
the best of our knowledge, this association has not been reported in a
lung cancer population previously.
4.2. Significant covariates
Patients surmised to have curable disease often wait longer for di-
agnosis and treatment initiation than patients with non-curative treat-
ment options. This has been explained by the increased number of di-
agnostic procedures necessary for accurate staging in early lung cancer
[18]. This was confirmed in our study where twice as many patients in
curative stages I-III needed four or more diagnostic procedures com-
pared with patients in stage IV. When correcting for number of proce-
dures and other covariates, low staging still remained a factor asso-
ciated with delayed diagnosis and treatment (Table 4). This finding is
supported by Ezer et al. [19], concluding in a multivariate model that
stage (I/II vs III/IV) was associated with longer TTT. Patients with stage
IV disease are more often admitted to hospital presenting a sympto-
matic disease, which often contributes to a quicker diagnosis and
thereby shorter TTT.
Out-of-house procedures were also associated with longer TTT.
Staging with PET-CT (adding 10.6 days) and external OUH procedure
(adding 13 days) were independent factors of delay. Transferring in-
formation, including diagnostic imaging and additional discussion in
once weekly MDT meetings with the referral hospital might explain
some of the experienced delay.
The finding of delay associated with the “no-biopsy” group can be
explained by the fact that these patients were exclusively treated with
SBRT, the treatment category with longest treatment interval.
Treatment could not be included in the regression analysis due too high
correlation with stage. It was also surprising that performing an MRI
was associated with shorter TTT. The most likely explanation is that we
made no distinction between cerebral MRI as a screening modality of
asymptomatic brain metastasis and MRI ordered due to emergency
symptoms. In the latter case, for instance in spinal cord affection, the
MRI was followed by quick initiation of treatment.
4.3. Intervals and guideline recommendations
Recent consensus based expert guidelines are fairly in alignment
with the Norwegian with a recommended 40 to 45 days from referral to
start of treatment depending on treatment given [11,12].
In the baseline period we found long TTT-intervals for all patients,
but especially for patients where curative treatment was intended.
Median TTT for surgery, SBRT and chemoradiation was reduced by
approximately two weeks in the period following the local initiative
(2013–2014). Interestingly there was a further median reduction of
approximately one week in TTT for all patients treated with curative
intent after the introduction of the NDCP in January 2015, i.e. 5 days,
13 days and 7 days for surgery, SBRT and chemoradiation, respectively.
The additional effect of NDCPs, could be explained by the clear in-
centives from the government and hospital administrators to make
conjoint efforts to reach recommended time limits. The entire diag-
nostic chain including pulmonary, radiologic, nuclear medicine and
pathologic services was primed and streamlined.
However, all improvements were performed without additional
national resources or funding.
The reasons for the various time intervals constituting the TTT vary
markedly. While the covariates discussed above mostly influence the
time spent in the diagnostic interval, the referral and treatment inter-
vals are more dependent on organizational and capacity factors.
Referral interval was median six days, at baseline, before im-
plementation of our local initiative in 2013 (Table 3). Careful daily
evaluation of referrals and having available prioritized slot times for
cancer diagnostics, enabled a reduced time to first consultation to four
Table 4
Univariable and multivariable median regression of total time to treatment
(TTT) in lung cancer patients, 2007–2016 (N = 780).
Unadjusted difference
(days)




in median TTT (95%
CI)
Diagnostic time period
2007–12 (baseline) Ref Ref
2013–14 (local initiative) −6 (−12.7, 0.7) −7.8 (−12.3,
−3.2)
2015–16 (national initiative) −11 (−17.0, −5.0) −14.9 (−19.6,
−10.2)
Age
per 10-years 4.8 (2.4, 7.2) 4.1 (2.3, 5.9)
Sex
Female Ref Ref
Male −4 (−9.0, 1.0) −1.7 (−5.0, 1.8)
Histology
Squamous cell c. Ref Ref
Non-squamous cell c. −9 (−14.2, −3.7) −1.0 (−5.0, 2.9)
No-biopsy 16 (5.0, 27.0) 12.8 (3.2, 21.0)
Procedure numbers
no. 8 (5.9, 10.1) 5.3 (3.3, 7.4)
Stage
I 36 (31.7, 40.3) 21.3 (15.9, 26.7)
II 25 (19.3, 30.7) 7.9 (1.4, 14.4)
III 18 (13.2, 22.8) 5.9 (0.8, 11.0)
IV Ref Ref
Treatment *
Surgery 27 (23.2, 30.8)
SBRT 39 (33.5, 44.5)
Chemoradiation 20 (14.4, 25,6)
Palliative Ref
PET-CT
Yes 26 (22.5, 29.5) 10.6 (5.5, 15.7)
No Ref Ref
MRI




Yes 28 (20.2, 35.8) 13.0 (6.9, 19.1)
No Ref Ref
Significant values in bold.
CI: confidence interval; SBRT: stereotactic beam radiation therapy; PET-CT:
positron emission tomography – computed tomography; MRI: magnetic re-
sonance imaging; OUH: Oslo University Hospital.
⁎ Not included in multivariable regression model due to multi-collinearity
with stage.
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days in 2013–14. This referral interval of four days is short compared to
other reports. In the review article by Jacobsen et al. [20] the median
referral interval was seven days with a range from 1–17 in the nine
studies reported.
While there was no difference in referral interval for patients ending
up receiving curative or palliative treatment, we found a marked dif-
ference between the two groups in the diagnostic interval (Table 3). The
shorter diagnostic time period of palliative patients often involves only
one CT scanning and one invasive diagnostic procedure. The two weeks
spent on the diagnostic work-up in this group did not change during our
study period. The longer diagnostic interval seen in curative patients
was however reduced from 36 to 21 days. This reduction occurred
despite an increase in mean number of diagnostic procedures from 3.5
in the baseline period to 3.9 after the national initiative. The reduced
delays in 2013–14 and 2015–16, is considered to be related to im-
proved coordination and the introduction of a logistically more efficient
path to treatment. More specifically, unnecessary diagnostic procedures
were avoided through preplanning the diagnostic work-up at referral.
Furthermore, procedures with presumed highest yields and staging
values were prioritized, and these procedures were often performed at
the day of the first consultation.
Despite the referral and diagnostic intervals being fairly similar
among the curative treatment modalities, there was a marked differ-
ence in TTT ranging from 28 days for chemoradiation of curative intent
to 51 days for SBRT. Most of these differences were due to the treatment
interval varying from six to 21 days. The longer delays were seen in the
out-of-house modalities surgery and SBRT. These delays in the treat-
ment interval depend highly upon the capacity of the separate treat-
ment modalities. The ability to adapt to and vary the number of
treatments to be initiated every week is important in order to avoid
capacity delays. Overall the mean treatment interval of six days in case
of chemoradiation with curative intent, 14 days of surgery and 21 days
of SBRT are in the low range of reported values in other studies, ranging
14–33 days [8,18,21].
The NDCP states that a typical diagnostic interval should be max-
imum 21 calendar days. This goal was achieved for 75% of the pallia-
tive patients, but only for 50% for patients treated with curative intent
in the 2015–16 diagnostic period. Still this was an improvement from
the 22% achieved in 2007–12
Comparison with other studies is made difficult by the lack of
consensus as to what intervals are reported. A diagnostic interval of
2–37 days has been reported [8]. In many of these studies the diag-
nostic interval was defined by date of biopsy, while additional staging
procedures and final treatment decision were not included. This was
also the case in a recent study from the Norwegian Cancer Registry with
national data for 2007–16. Here the time interval from diagnosis (date
of biopsy) to surgery or start curative intent radiotherapy for lung
cancer was found to decrease from 2010 before and after introduction
of national cancer pathways in 2015 [22]. The capacity to initiate
treatment, i.e. treatment interval, was not measured in the national
study.
4.4. Strengths
The study cohort is based on a complete, unselected lung cancer
population spanning a period of 10 years. This gives an overview of the
effects of the diagnostic periods and should comply with a sound ex-
ternal validity for other hospitals treating lung cancer. A quantile re-
gression model, enabling us to estimate the impact of initiatives on
different lengths of TTT, gives added understanding to interpretation of
delays.
4.5. Weaknesses
Although data from 2013 were prospectively collected, the patient
data prior to this were retrieved using electronic records. This makes
them susceptible to bias. Our diagnostic chain involves two hospitals
for most of the patients treated with curative intent, either through
diagnostic PET-CT or treatment with surgery or SBRT. Thus, general-
izability may also be limited in set ups were all diagnostics and treat-
ments are located in the same hospital.
5. Conclusions
This study demonstrates that it is possibly to shorten both time
spent on diagnostic work-up and the successive time spent waiting for
treatment. Our experience shows that this can be done by rather small
logistic changes by focusing on removing unnecessary delays. Both
local and national initiatives regarding time intervals are of importance
in this process. More importantly, this reduction can be achieved even
in a period where new diagnostic procedures and a more aggressive
attitude to tissue sampling and staging are introduced. This is especially
Fig. 2. Percentage of patients receiving timely treatment according to recommendations in Norwegian diagnostic cancer pathways.
A TTT of 35 days or less is regarded as timely for chemotherapy and 42 days or less for surgery or radiotherapy. SBRT: stereotactic bean radiation therapy.
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important in a time where more effective treatment options are be-
coming available.
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